blue cross blue shield of michigan glp 1 coverage Does cover Zepbound? Blue Cross Blue Shield of

By Patricia Van Arnum, Editorial Director, DCAT, [email protected] Lilly and Novo Nordisk battle in oral obesity drug market The battle in the obesity drug market is heating up as this week (April 1, 2026) Eli Lilly and Company reported that it had received approval from the US Food and Drug Administration (FDA) for its oral obesity drug, Foundayo (orforglipron)

Patients with non-alcoholic steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD) with concurrent diabetes or obesity might benefit from the hepatic anti-inflammatory effects observed in clinical studies, though GLP-1 receptor agonists are not yet FDA-approved specifically for liver disease

L-carnitina: lo importante en simple La L-carnitina no es magia Es un apoyo para usar la grasa como energa, pero funciona mejor cuando te mueves No quema grasa por s sola Es ms efectiva con ejercicio La dosis correcta s importa Por eso, no todos necesitan lo mismo

(2) Raun K, Hansen BS, Johansen NL, Thgersen H, Madsen K, Ankersen M, Andersen PH